$ARTH
Arch Therapeutics, Inc.

2016 Q1 Form 10-Q Financial Statement

#000114420416081344 Filed on February 12, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $870.0K $870.0K $870.0K
YoY Change 2.35% 0.0% 67.31%
% of Gross Profit
Research & Development $386.3K $414.0K $399.7K
YoY Change -4.03% 3.57% 55.4%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $1.255M $1.280M $1.270M
YoY Change -0.08% 0.74% 62.69%
Operating Profit -$1.255M -$1.280M -$1.270M
YoY Change -0.08% 0.74% 62.69%
Interest Expense $66.82K $143.7K $27.77K
YoY Change 32.18% 417.73% 0.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.250M -$1.160M $380.0K
YoY Change 50.6% -405.26% -146.91%
Income Tax
% Of Pretax Income
Net Earnings -$1.253M -$1.157M $379.1K
YoY Change 50.25% -405.07% -146.9%
Net Earnings / Revenue
Basic Earnings Per Share $0.01
Diluted Earnings Per Share -$11.41K -$0.01 $0.01
COMMON SHARES
Basic Shares Outstanding 109.6M shares 73.34M shares
Diluted Shares Outstanding 108.6M shares 73.42M shares

Balance Sheet

Concept 2016 Q1 2015 Q4 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.670M $2.820M $780.0K
YoY Change 192.98% 261.54% -17.89%
Cash & Equivalents $1.669M $2.815M $782.7K
Short-Term Investments
Other Short-Term Assets $90.00K $50.00K $40.00K
YoY Change 200.0% 25.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.759M $2.868M $820.0K
YoY Change 190.31% 249.81% -16.75%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $632.00 $0.00 $4.441K
YoY Change -100.0% -57.23%
TOTAL ASSETS
Total Short-Term Assets $1.759M $2.868M $820.0K
Total Long-Term Assets $632.00 $0.00 $4.441K
Total Assets $1.760M $2.868M $824.4K
YoY Change 190.41% 247.92% -17.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $140.0K $267.9K $294.2K
YoY Change -31.41% -8.95% -4.97%
Accrued Expenses $160.0K $150.0K $280.0K
YoY Change -51.52% -46.43% 40.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $270.0K
YoY Change -75.61%
Total Short-Term Liabilities $400.0K $748.7K $995.0K
YoY Change -71.27% -24.75% 94.03%
LONG-TERM LIABILITIES
Long-Term Debt $970.0K $970.0K $960.0K
YoY Change 1.04% 1.04% 1.05%
Other Long-Term Liabilities $270.0K $240.0K $4.300M
YoY Change -93.54% -94.42% 14233.33%
Total Long-Term Liabilities $1.243M $1.210M $5.256M
YoY Change -75.84% -76.98% 440.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $400.0K $748.7K $995.0K
Total Long-Term Liabilities $1.243M $1.210M $5.256M
Total Liabilities $1.642M $1.959M $6.251M
YoY Change -74.88% -68.67% 320.86%
SHAREHOLDERS EQUITY
Retained Earnings -$18.13M -$16.88M -$12.40M
YoY Change 37.06% 36.17%
Common Stock $18.14M $17.79M $76.08K
YoY Change 148.47% 23282.89% 26.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $120.0K $909.9K -$5.426M
YoY Change
Total Liabilities & Shareholders Equity $1.760M $2.868M $824.4K
YoY Change 190.41% 247.92% -17.18%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2014 Q4
OPERATING ACTIVITIES
Net Income -$1.253M -$1.157M $379.1K
YoY Change 50.25% -405.07% -146.9%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change
Cash From Operating Activities -$1.190M -$1.140M -$850.8K
YoY Change 23.96% 33.98% 39.04%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 0.000 $800.0K
YoY Change -94.67% -100.0% -20.0%
NET CHANGE
Cash From Operating Activities -1.190M -1.140M -$850.8K
Cash From Investing Activities
Cash From Financing Activities 40.00K 0.000 $800.0K
Net Change In Cash -1.150M -1.140M -$50.85K
YoY Change 447.62% 2142.11% -113.1%
FREE CASH FLOW
Cash From Operating Activities -$1.190M -$1.140M -$850.8K
Capital Expenditures $0.00
Free Cash Flow -$1.140M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
42919 USD
CY2015Q4 us-gaap Assets
Assets
2868409 USD
CY2015Q3 us-gaap Assets
Assets
4003019 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
267863 USD
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
231761 USD
CY2015Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
146429 USD
CY2015Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
245478 USD
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
68485 USD
CY2015Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
335092 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
748675 USD
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1286078 USD
CY2015Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
969589 USD
CY2015Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
966824 USD
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
240250 USD
CY2015Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
210000 USD
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1209839 USD
CY2015Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1176824 USD
CY2015Q4 us-gaap Liabilities
Liabilities
1958514 USD
CY2015Q4 us-gaap Cash
Cash
2815449 USD
CY2015Q3 us-gaap Cash
Cash
3960100 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
52960 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
2868409 USD
CY2015Q3 us-gaap Assets Current
AssetsCurrent
4003019 USD
CY2015Q3 us-gaap Liabilities
Liabilities
2462902 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
109172 USD
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
107392 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17679598 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16878875 USD
CY2014Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
870355 USD
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
865512 USD
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
414003 USD
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
1270090 USD
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
1279515 USD
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1270090 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1279515 USD
CY2014Q4 us-gaap Interest Expense
InterestExpense
27765 USD
CY2015Q4 us-gaap Interest Expense
InterestExpense
143747 USD
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
2753170 USD
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
137146 USD
CY2014Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1649235 USD
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15722220 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
909895 USD
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
1540117 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2868409 USD
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4003019 USD
CY2015Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
265898 USD
CY2015Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
473747 USD
CY2014Q4 us-gaap Revenues
Revenues
0 USD
CY2015Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
122860 USD
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17154945 USD
CY2015Q4 us-gaap Revenues
Revenues
0 USD
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
379145 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-1156655 USD
CY2014Q4 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
224000 USD
CY2015Q4 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
129461 USD
CY2014Q4 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
1300170 USD
CY2015Q4 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
0 USD
CY2014Q4 us-gaap Share Based Compensation
ShareBasedCompensation
278212 USD
CY2015Q4 us-gaap Share Based Compensation
ShareBasedCompensation
148037 USD
CY2014Q4 arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
27764 USD
CY2015Q4 arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
143747 USD
CY2014Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1704 USD
CY2015Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10041 USD
CY2014Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
118350 USD
CY2015Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
36102 USD
CY2014Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
12355 USD
CY2015Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-91734 USD
CY2014Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-850845 USD
CY2015Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1144651 USD
CY2014Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
399735 USD
CY2014Q4 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
800000 USD
CY2015Q4 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2014Q4 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-50845 USD
CY2015Q4 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1144651 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
833520 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3960100 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
782675 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2815449 USD
CY2014Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
800000 USD
CY2015Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2014Q4 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-2753170 USD
CY2015Q4 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-137146 USD
CY2014Q4 arth Change To Gain Or Loss On Warrant Modification
ChangeToGainOrLossOnWarrantModification
-1300170 USD
CY2015Q4 arth Change To Gain Or Loss On Warrant Modification
ChangeToGainOrLossOnWarrantModification
0 USD
CY2015Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
325896 USD
CY2014Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2015Q4 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-52500 USD
CY2014Q4 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-8625 USD
CY2015Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
969589 USD
CY2015Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
966824 USD
CY2013Q2 arth Increase In Aggregate Number Of Shares
IncreaseInAggregateNumberOfShares
3000000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.766 pure
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.194 pure
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0106 pure
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.024 pure
CY2015Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.00 pure
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10776500 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2015Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
37500 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10739000 shares
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
8849563 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10739000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.38
CY2015Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2015Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2015Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm
P0Y
CY2015Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
P0Y
CY2015Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
P0Y
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M17D
CY2015Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P4Y7M28D
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y7M17D
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2015Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue
0 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2015Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue
0 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
51400 USD
CY2015Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
35567 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
51400 USD
CY2015Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.22
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.3
CY2015Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
0.32
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.3
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4381704 shares
CY2015Q1 us-gaap Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral
354988 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
395012 USD
CY2015Q4 dei Document Type
DocumentType
10-Q
CY2015Q4 dei Amendment Flag
AmendmentFlag
false
CY2015Q4 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2015Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q4 dei Entity Registrant Name
EntityRegistrantName
Arch Therapeutics, Inc.
CY2015Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001537561
CY2015Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2015Q4 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q4 dei Trading Symbol
TradingSymbol
ARTH
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
109574100 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109171684 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109171684 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107592205 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107592205 shares
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.01
CY2015Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
108620575 shares
CY2014Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
73337085 shares
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2015Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108620575 shares
CY2014Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73422007 shares
CY2015Q4 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Concentration of Credit Risk</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
2765 USD
CY2014Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
224000 USD
CY2014Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
2765 USD

Files In Submission

Name View Source Status
0001144204-16-081344-index-headers.html Edgar Link pending
0001144204-16-081344-index.html Edgar Link pending
0001144204-16-081344.txt Edgar Link pending
0001144204-16-081344-xbrl.zip Edgar Link pending
arth-20151231.xml Edgar Link completed
arth-20151231.xsd Edgar Link pending
arth-20151231_cal.xml Edgar Link unprocessable
arth-20151231_def.xml Edgar Link unprocessable
arth-20151231_lab.xml Edgar Link unprocessable
arth-20151231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v429792_10q.htm Edgar Link pending
v429792_ex31-1.htm Edgar Link pending
v429792_ex31-2.htm Edgar Link pending
v429792_ex32-1.htm Edgar Link pending